Showing 5741-5750 of 6035 results for "".
- MacuLogix Hosts Inaugural AMD Speaker Alliancehttps://modernod.com/news/maculogix-hosts-inaugural-amd-speaker-alliance/2476336/MacuLogix hosted the industry’s first AMD Speaker Alliance meeting. The peer-to-peer event was attended by 25 optometric key opinion leaders who are at the front lines of minimizing vision loss due to AMD and other retinal disease. “This meeting is helping us kick off a movement in our pro
- University of Alberta Scientists Pinpoint a Cause of Pigmentary Glaucomahttps://modernod.com/news/university-of-alberta-scientists-pinpoint-a-cause-of-pigmentary-glaucoma/2476337/An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition. “People who traditionally we wouldn’t think of having glaucoma—young males in their 20s and 30s—are at particular risk
- Investigators Seek Optimized Ophthalmology Clinical Trial Outcomeshttps://modernod.com/news/investigators-seek-optimized-ophthalmology-clinical-trial-outcomes/2476338/Investigators from Brown University and Johns Hopkins University shared new considerations from 3 groups working to standardize Core Outcome Sets (COSs), to increase the utility of results from randomized clinical trials for 3 eye conditions: age-related macular degeneration (AMD), refractive err
- Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMDhttps://modernod.com/news/ranibizumab-and-aflibercept-prompt-comparable-visual-gain-in-amd/2476339/In patients with neovascular age-related macular degeneration (AMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers, as reported by Reuters. In a January 24 online paper in JAMA Ophthalmology, Dr. Mark C. Gillies of Sy
- Lutronic Vision Initiates Preclinical Trial of R:GEN Laser for the Treatment of Dry AMDhttps://modernod.com/news/lutronic-vision-initiates-preclinical-trial-of-rgen-laser-for-the-treatment-of-dry-amd/2476343/Lutronic Vision announced that it has initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). This study has been initiated at the University of Southern California with Stan Louie, PharmD, Pr
- Controlled Trial Shows Promise of Donated Stem Cells in Restoring Visionhttps://modernod.com/news/controlled-trial-shows-promise-of-donated-stem-cells-in-restoring-vision/2476345/A study in STEM CELLS Translational Medicine provides a deeper and clearer understanding of how patients suffering vision loss in both eyes due to limbal stem cell deficiency (LSCD) might benefit from a stem cell transplant using donated cells. This is the first ra
- Multicolor Holography Technology Could Enable Extremely Compact 3D Displayshttps://modernod.com/news/multicolor-holography-technology-could-enable-extremely-compact-3d-displays/2479595/Researchers have developed a new approach to multicolor holography that could be used to make 3D color displays for augmented reality glasses, smartphones, or heads-up displays without any bulky optical components. In Optica, researchers from Duke University, describe how they encod
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi
- EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directorshttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-guyer-md-to-board-of-directors/2479602/EyePoint Pharmaceuticals announced the appointment of David Guyer, MD, to the company’s Board of Directors. He will also serve on the company’s Science Committee. Dr. Guyer has led several public and private biotechnology companies focused on ocular diseases, and has held leadership positi
- FDA Commissioner Gottlieb Announces Efforts to Improve Assessment of REMS Programshttps://modernod.com/news/fda-commissioner-gottlieb-announces-efforts-to-improve-assessment-of-rems-programs/2479604/In an FDA statement, Commissioner Scott Gottlieb, MD, announced efforts to improve the quality of the information used to assess the effectiveness of Risk Evaluation and Mitigation Strategy (REMS) programs in supporting the safe use of medications. In making decisions about whether the ben